Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 NGS Pre-Sequencing
1.2.3 Sequencing
1.2.4 NGS Data Analysis
1.2.5 Primary, Secondary & Tertiary Data Analysis
1.3 Market by Application
1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Academic & Clinical Research
1.3.3 Hospitals & Clinics
1.3.4 Pharma & Biotech Entities
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2018-2033)
2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Region
2.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Region (2018-2023)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2024-2033)
2.3 Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
2.3.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Trends
2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
2.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2018-2023)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2018-2023)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2022
3.5 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.6 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.7 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2018-2023)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2033)
5 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2018-2023)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2033)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2033)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2033)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023)
8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2033)
9.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
9.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2033)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.3.5 Agilent Technologies Recent Development
11.4 Knome
11.4.1 Knome Company Detail
11.4.2 Knome Business Overview
11.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.4.5 Knome Recent Development
11.5 Genomatix Software
11.5.1 Genomatix Software Company Detail
11.5.2 Genomatix Software Business Overview
11.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.5.5 Genomatix Software Recent Development
11.6 GATC Biotech
11.6.1 GATC Biotech Company Detail
11.6.2 GATC Biotech Business Overview
11.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.6.5 GATC Biotech Recent Development
11.7 Oxford Nanopore Technologies
11.7.1 Oxford Nanopore Technologies Company Detail
11.7.2 Oxford Nanopore Technologies Business Overview
11.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.7.5 Oxford Nanopore Technologies Recent Development
11.8 Macrogen
11.8.1 Macrogen Company Detail
11.8.2 Macrogen Business Overview
11.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.8.5 Macrogen Recent Development
11.9 Life Technologies
11.9.1 Life Technologies Company Detail
11.9.2 Life Technologies Business Overview
11.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.9.5 Life Technologies Recent Development
11.10 DNASTAR
11.10.1 DNASTAR Company Detail
11.10.2 DNASTAR Business Overview
11.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.10.5 DNASTAR Recent Development
11.11 Exosome Diagnostics
11.11.1 Exosome Diagnostics Company Detail
11.11.2 Exosome Diagnostics Business Overview
11.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.11.5 Exosome Diagnostics Recent Development
11.12 Biomatters
11.12.1 Biomatters Company Detail
11.12.2 Biomatters Business Overview
11.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.12.5 Biomatters Recent Development
11.13 CLC Bio
11.13.1 CLC Bio Company Detail
11.13.2 CLC Bio Business Overview
11.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.13.5 CLC Bio Recent Development
11.14 BGI
11.14.1 BGI Company Detail
11.14.2 BGI Business Overview
11.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.14.5 BGI Recent Development
11.15 Qiagen
11.15.1 Qiagen Company Detail
11.15.2 Qiagen Business Overview
11.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.15.5 Qiagen Recent Development
11.16 Perkin Elmer
11.16.1 Perkin Elmer Company Detail
11.16.2 Perkin Elmer Business Overview
11.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.16.5 Perkin Elmer Recent Development
11.17 Pacific Bioscience
11.17.1 Pacific Bioscience Company Detail
11.17.2 Pacific Bioscience Business Overview
11.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.17.5 Pacific Bioscience Recent Development
11.18 Partek
11.18.1 Partek Company Detail
11.18.2 Partek Business Overview
11.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.18.5 Partek Recent Development
11.19 GnuBIO
11.19.1 GnuBIO Company Detail
11.19.2 GnuBIO Business Overview
11.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.19.5 GnuBIO Recent Development
11.20 Foundation Medicine
11.20.1 Foundation Medicine Company Detail
11.20.2 Foundation Medicine Business Overview
11.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.20.5 Foundation Medicine Recent Development
11.21 Paradigm
11.21.1 Paradigm Company Detail
11.21.2 Paradigm Business Overview
11.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.21.5 Paradigm Recent Development
11.22 Caris Life Sciences
11.22.1 Caris Life Sciences Company Detail
11.22.2 Caris Life Sciences Business Overview
11.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.22.5 Caris Life Sciences Recent Development
11.23 Myriad Genetics
11.23.1 Myriad Genetics Company Detail
11.23.2 Myriad Genetics Business Overview
11.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
11.23.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of NGS Pre-Sequencing
Table 3. Key Players of Sequencing
Table 4. Key Players of NGS Data Analysis
Table 5. Key Players of Primary, Secondary & Tertiary Data Analysis
Table 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2018-2023)
Table 10. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2024-2033)
Table 12. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
Table 13. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Table 14. Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
Table 15. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
Table 16. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players (2018-2023)
Table 18. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
Table 19. Ranking of Global Top Clinical Oncology Next Generation Sequencing (NGS) Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
Table 23. Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2018-2023)
Table 27. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2024-2033)
Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2018-2023)
Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2024-2033)
Table 33. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2033) & (US$ Million)
Table 48. Illumina Company Detail
Table 49. Illumina Business Overview
Table 50. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product
Table 51. Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 52. Illumina Recent Development
Table 53. Roche Company Detail
Table 54. Roche Business Overview
Table 55. Roche Clinical Oncology Next Generation Sequencing (NGS) Product
Table 56. Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 57. Roche Recent Development
Table 58. Agilent Technologies Company Detail
Table 59. Agilent Technologies Business Overview
Table 60. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 61. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 62. Agilent Technologies Recent Development
Table 63. Knome Company Detail
Table 64. Knome Business Overview
Table 65. Knome Clinical Oncology Next Generation Sequencing (NGS) Product
Table 66. Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 67. Knome Recent Development
Table 68. Genomatix Software Company Detail
Table 69. Genomatix Software Business Overview
Table 70. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product
Table 71. Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 72. Genomatix Software Recent Development
Table 73. GATC Biotech Company Detail
Table 74. GATC Biotech Business Overview
Table 75. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product
Table 76. GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 77. GATC Biotech Recent Development
Table 78. Oxford Nanopore Technologies Company Detail
Table 79. Oxford Nanopore Technologies Business Overview
Table 80. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 81. Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 82. Oxford Nanopore Technologies Recent Development
Table 83. Macrogen Company Detail
Table 84. Macrogen Business Overview
Table 85. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product
Table 86. Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 87. Macrogen Recent Development
Table 88. Life Technologies Company Detail
Table 89. Life Technologies Business Overview
Table 90. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 91. Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 92. Life Technologies Recent Development
Table 93. DNASTAR Company Detail
Table 94. DNASTAR Business Overview
Table 95. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product
Table 96. DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 97. DNASTAR Recent Development
Table 98. Exosome Diagnostics Company Detail
Table 99. Exosome Diagnostics Business Overview
Table 100. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product
Table 101. Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 102. Exosome Diagnostics Recent Development
Table 103. Biomatters Company Detail
Table 104. Biomatters Business Overview
Table 105. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product
Table 106. Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 107. Biomatters Recent Development
Table 108. CLC Bio Company Detail
Table 109. CLC Bio Business Overview
Table 110. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product
Table 111. CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 112. CLC Bio Recent Development
Table 113. BGI Company Detail
Table 114. BGI Business Overview
Table 115. BGI Clinical Oncology Next Generation Sequencing (NGS) Product
Table 116. BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 117. BGI Recent Development
Table 118. Qiagen Company Detail
Table 119. Qiagen Business Overview
Table 120. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product
Table 121. Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 122. Qiagen Recent Development
Table 123. Perkin Elmer Company Detail
Table 124. Perkin Elmer Business Overview
Table 125. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product
Table 126. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 127. Perkin Elmer Recent Development
Table 128. Pacific Bioscience Company Detail
Table 129. Pacific Bioscience Business Overview
Table 130. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product
Table 131. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 132. Pacific Bioscience Recent Development
Table 133. Partek Company Detail
Table 134. Partek Business Overview
Table 135. Partek Clinical Oncology Next Generation Sequencing (NGS) Product
Table 136. Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 137. Partek Recent Development
Table 138. GnuBIO Company Detail
Table 139. GnuBIO Business Overview
Table 140. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product
Table 141. GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 142. GnuBIO Recent Development
Table 143. Foundation Medicine Company Detail
Table 144. Foundation Medicine Business Overview
Table 145. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product
Table 146. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 147. Foundation Medicine Recent Development
Table 148. Paradigm Company Detail
Table 149. Paradigm Business Overview
Table 150. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product
Table 151. Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 152. Paradigm Recent Development
Table 153. Caris Life Sciences Company Detail
Table 154. Caris Life Sciences Business Overview
Table 155. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product
Table 156. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 157. Caris Life Sciences Recent Development
Table 158. Myriad Genetics Company Detail
Table 159. Myriad Genetics Business Overview
Table 160. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product
Table 161. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
Table 162. Myriad Genetics Recent Development
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type: 2022 VS 2033
Figure 3. NGS Pre-Sequencing Features
Figure 4. Sequencing Features
Figure 5. NGS Data Analysis Features
Figure 6. Primary, Secondary & Tertiary Data Analysis Features
Figure 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2022 VS 2033
Figure 9. Academic & Clinical Research Case Studies
Figure 10. Hospitals & Clinics Case Studies
Figure 11. Pharma & Biotech Entities Case Studies
Figure 12. Clinical Oncology Next Generation Sequencing (NGS) Report Years Considered
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region: 2022 VS 2033
Figure 16. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players in 2022
Figure 17. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2022
Figure 19. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2033)
Figure 21. United States Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2033)
Figure 25. Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2018-2033)
Figure 33. China Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2033)
Figure 41. Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2033)
Figure 45. Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Illumina Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 48. Roche Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 49. Agilent Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 50. Knome Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 51. Genomatix Software Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 52. GATC Biotech Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 53. Oxford Nanopore Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 54. Macrogen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 55. Life Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 56. DNASTAR Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 57. Exosome Diagnostics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 58. Biomatters Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 59. CLC Bio Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 60. BGI Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 61. Qiagen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 62. Perkin Elmer Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 63. Pacific Bioscience Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 64. Partek Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 65. GnuBIO Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 66. Foundation Medicine Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 67. Paradigm Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 68. Caris Life Sciences Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 69. Myriad Genetics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed